Table 3.
Major Atherothrombotic Events in acute coronary syndrome and Chronic Coronary Syndrome (Non‐ACS) Subgroups by CYP2C19 and Antiplatelet Therapy
| Major atherothrombotic events by CYP2C19‐P2Y12 inhibitor | Event no. (%)* | Event rate (per 100 ) † | Unadjusted HR (95% CI) | P value | Adjusted HR ‡ (95% CI) | P value |
|---|---|---|---|---|---|---|
| ACS | ||||||
| LOF‐clopidogrel | 60 (19.6) | 46.3 | Reference | Reference | ||
| LOF‐alternative | 38 (9.2) | 17.8 | 0.39 (0.26–0.59) | <0.001 | 0.49 (0.32–0.76) | 0.001 |
| Non‐LOF‐clopidogrel | 154 (12.0) | 23.8 | Reference | Reference | ||
| Non‐LOF‐alternative | 28 (9.7) | 19.6 | 0.82 (0.55–1.23) | 0.346 | 1.05 (0.67–1.66) | 0.834 |
| Non‐ACS | ||||||
| LOF‐clopidogrel | 11 (7.1) | 14.3 | Reference | Reference | ||
| LOF‐alternative | 13 (8.2) | 15.2 | 1.06 (0.48–2.37) | 0.883 | 1.02 (0.44–2.36) | 0.957 |
| Non‐LOF‐clopidogrel | 43 (6.6) | 12.5 | Reference | Reference | ||
| Non‐LOF‐alternative | 6 (6.8) | 13.3 | 1.03 (0.44–2.42) | 0.946 | 0.74 (0.30–1.84) | 0.522 |
ACS indicates acute coronary syndrome; and LOF, loss‐of‐function.
*
Data are presented as the number (%) of patients in each group who experienced the event over 12 months of follow‐up after the index PCI.
†
The event rate was calculated as the number of events per 100 patient‐years of follow‐up.
‡
The HR was adjusted with inverse probability weights derived from exposure propensity scores.